- 2 days ago
- 7 min read
Key Takeaways |
Ms. Chen became the first patient in China to achieve complete remission on a commercially approved CAR-T product, days after the drug's national approval — treated at a top-ranked 3A-grade hospital in Shanghai. |
She had relapsed/refractory diffuse large B-cell lymphoma (DLBCL) — a group in which roughly 40–50% of patients relapse after first-line treatment, and 73% of relapsed/refractory patients fail to reach remission even with second-line therapy and beyond. |
From prescription to infusion took about five weeks: T-cell collection, off-site manufacturing, and reinfusion — a timeline consistent with standard commercial CAR-T turnaround globally. |
Initial PET-CT after infusion showed complete remission, with the hospital's hematology team stating that long-term follow-up is still needed to confirm durability. |
Introduction
Every national CAR-T program has a "patient zero" — the first person treated after a product moves from clinical trial to full commercial approval. In China, that patient was Ms. Chen, an elderly woman with relapsed diffuse large B-cell lymphoma who had run out of options after first- and second-line treatment failed. Her discharge in August 2021, in complete remission, marked a symbolic and clinical milestone: the point where CAR-T in China stopped being something only available inside a trial and became a therapy any eligible patient could, in principle, access.
This case adds to our library of documented CAR-T outcomes in China alongside our coverage of the "Beijing Protocol" allogeneic CAR-T breakthrough and a separate refractory-lymphoma case at a top Shanghai cancer hospital — together, these cases span two major Chinese cities and multiple hospital systems, illustrating that CAR-T capability in China isn't concentrated at a single institution. For the fuller picture on where CAR-T is available and what it costs, see our CAR-T treatment guide.
The Patient's Situation Before CAR-T
Patient: Ms. Chen (pseudonym), an elderly patient
Diagnosis: Relapsed diffuse large B-cell lymphoma (DLBCL), originally diagnosed in July 2019
Disease course: Relapsed after first-line treatment; second-line treatment was ineffective
Why the timing mattered: On June 22, 2021, China's first commercially approved CAR-T cell therapy drug received marketing approval — opening a treatment path for Ms. Chen that hadn't existed days earlier
According to the treating hematology team, relapsed/refractory DLBCL carries a serious prognosis: published data cited by the hospital shows a meta-analysis of 603 patients with relapsed or refractory DLBCL found a median overall survival of only 6.3 months — underscoring how limited the alternatives were for a patient in Ms. Chen's position.
The Medical Team & Institution
A top-ranked 3A-grade hospital affiliated with a leading medical university in Shanghai — its Department of Hematology has spent over a decade building what is described as the largest lymphoma biobank in China and a molecular subtyping gene profile of diffuse large B-cell lymphoma, used to support precision diagnosis and treatment nationally.
The hospital's Vice President and Professor of Hematology, Zhao Weili — led the team that decided, after thorough discussion with Ms. Chen's family, to pursue the newly approved CAR-T therapy.
Associate Chief Physician Xu Pengpeng, from the same hematology team, prescribed the treatment.
The hospital's National Translational Medicine Center nursing team carried out T-cell collection.
Treatment Timeline
Date | Milestone |
July 2019 | Diffuse large B-cell lymphoma diagnosed |
— | Relapse after first-line treatment; second-line treatment ineffective |
June 22, 2021 | First commercially approved CAR-T drug receives marketing approval in China |
June 28, 2021 | CAR-T treatment prescribed |
June 30, 2021 | T-cell collection completed |
August 2, 2021 | CAR-T cell infusion completed |
Shortly after infusion | Initial PET-CT scan shows complete remission |
August 26, 2021 | Ms. Chen discharged from the hospital |
Zhao Weili explained the mechanism behind the therapy: "CAR-T is a very effective immunotherapy method. It involves genetically modifying the patient's own T cells, introducing a chimeric antigen receptor gene into the T cells, thereby producing chimeric antigen receptor proteins on the surface of the T cells. After transduction, the antigen receptor proteins on the surface of the T cells will bind to and kill tumor cells expressing CD19."
She added that post-infusion imaging showed no detectable cancer cells in Ms. Chen's body, while noting that further long-term follow-up data is needed: "We also hope that more patients can achieve long-term remission and ultimately achieve cancer-free survival."
What Patients Say About ChinaCureLink & Medebound HEALTH
China CureLink operates under Medebound HEALTH — an internationally recognized healthcare navigation company incorporated in New York, with operations across North America and Asia-Pacific.
Rated 4.6 ⭐⭐⭐⭐⭐ at Trustpilot
Medebound HEALTH's online testimonials. Learn More
★★★★☆ Sarah Zhang · Canada· Jul 2024 · Verified “The interpreter during the video call was fantastic — super professional and answered all our questions clearly and quickly. The professor was also very patient and gave us detailed and honest guidance on our treatment options.” |
★★★★★ Andrew Goh · Singapore · Aug 2024 · Verified “My first contact with Medebound was over a year ago. Jason has always been responsive, even when I wasn't ready to proceed. When I finally did, the consultation was seamlessly arranged and the specialist was outstanding.” |
★★★★★ Daniel Wong · Singapore · Aug 2024 · Verified “I have dry eye and nothing seemed to be working, even with different medications. I heard about a medication from the U.S. that’s supposed to be really effective, but I didn’t want to try it without talking to a doctor first. MEDEBOUND connected me with a top ophthalmologist in the U.S. and it was so reassuring to get their expert advice.” |
What This Case Reflects About CAR-T Access in China
Ms. Chen's case is notable less for being clinically unusual and more for its timing: it demonstrates how quickly a newly commercially approved CAR-T product moved from regulatory approval to real-world patient use — prescription came six days after national approval, and infusion followed about five weeks after that. For international patients researching CAR-T access, this timeline is a useful benchmark for how fast a well-resourced Chinese hematology center can move once a product is approved and a patient is deemed eligible.
The broader clinical context reinforces why this mattered: with 40–50% of DLBCL patients eventually relapsing after first-line treatment, and the majority of relapsed/refractory patients failing subsequent lines of therapy, commercial CAR-T access represented what the treating team called a potentially life-saving one-time treatment option, with the potential for meaningfully better remission and survival rates than prior standards of care.
Reading This Case With the Right Caveats
"Complete remission" here refers to an initial post-infusion PET-CT finding, not confirmed long-term cure. The hospital's own hematologist stated explicitly that further long-term follow-up is needed.
DLBCL relapse risk after CAR-T is real and well documented in the broader literature — CAR-T significantly improves outcomes for relapsed/refractory DLBCL compared to prior standard therapies, but not every patient achieves durable remission, and relapse after initial response does occur in a meaningful subset of patients.
For international patients and families evaluating CAR-T therapy in China, ChinaCureLink helps with hospital selection, eligibility screening, and end-to-end coordination.
Frequently Asked Questions
Was this the first CAR-T treatment ever given in China, or the first on a commercially approved drug?
The first commercially approved product — Ms. Chen was treated shortly after China's first CAR-T cell therapy drug received national marketing approval, distinguishing this from earlier trial-stage CAR-T cases (such as academic haploidentical protocols used in clinical trials before commercial approval).
How long did the process take from diagnosis to remission?
Ms. Chen was originally diagnosed in July 2019. Once the CAR-T drug was approved in June 2021, the process from prescription to infusion took about five weeks, with complete remission confirmed on the initial post-infusion PET-CT scan and discharge following roughly three weeks after infusion.
What is diffuse large B-cell lymphoma (DLBCL), and why is relapsed/refractory DLBCL hard to treat?
DLBCL is the most common type of non-Hodgkin lymphoma. Published data indicates 40–50% of patients relapse after initial treatment, and about 73% of relapsed/refractory patients don't achieve remission even with second-line and later therapies — a meta-analysis of 603 such patients found a median overall survival of only 6.3 months, highlighting the unmet need CAR-T is designed to address.
How does CAR-T therapy work for DLBCL?
CAR-T therapy genetically modifies a patient's own T cells to express a chimeric antigen receptor that recognizes CD19, a protein found on the surface of the lymphoma cells. Once reinfused, these modified T cells bind to and kill CD19-expressing tumor cells.
Where can I learn more about CAR-T cost and hospital options in China?
References
Shangguan News, "The first patient in China to receive CAR-T therapy was discharged from hospital, assessed as having achieved complete remission", August 29, 2021 — original source case report.
"China's first CAR-T Cell Therapy approved – Fosun Kite Axicabtagene Ciloleucel (FKC876)", BioSpace — corroborates June 2021 first CAR-T drug approval in China and the treating hematologist's role as lead investigator on the approval trial.
"Recent advances in CAR T-cell therapy for lymphoma in China", PMC — background on China's CAR-T regulatory and clinical landscape.
About ChinaCureLink
ChinaCureLink helps patients across the world access the best cancer treatment at China's top hospitals, without the delays, language barriers, and administrative confusion that typically come with seeking care abroad.
We connect patients directly with China's top cancer hospitals, ensuring that from the first case submission through to treatment and follow-up, every step is guided, translated, and coordinated by a team experienced in cross-border patient care.
ChinaCureLink is proudly affiliated with Medebound HEALTH — an international medical concierge company headquartered in New York, specialized in securing premium second opinions from top US hospitals and specialists. With over 10 years of experience and more than 3,000 patients served worldwide, Medebound HEALTH is recognized as one of the leading patient access services across North America and the Asia-Pacific, bringing the same standard of expert care coordination to every patient we serve.
Disclaimer
This article is for informational purposes only and does not constitute medical or financial advice. Treatment eligibility, protocols, and outcomes vary by individual patient and disease subtype. Please confirm specifics with a qualified oncologist or a ChinaCureLink coordinator before making treatment decisions.
Comments